Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Q1 2024 Earnings Presentation
19 slides from Imricor Medical Systems's earnings presentation, Apr 30, 2024
Slide 1: Q1 CY 2024 Results
For personal use only Q1 CY 2024 Results 30th April 2024 (29th April 2024 US) IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) WWW.IMRICOR.COM
Slide 2: Imricor is the global leader in MRI compatible tools for cardiac interventions
Imricor is the global leader in design and manufacture of For personal use only MRI compatible tools for cardiac interventions. • Large unmet need (US$ 8billion p.a market) • Proven technology – safe and effective with 70 global patents • Leading Hospitals as customers • Captures 100% of recurring c
Slide 3: Physician quote on NorthStar in the iCMR
For personal use only "What may have taken several hours in the x-ray lab took less than an hour to perform using NorthStar in the iCMR." Dr. Marco Götte - Amsterdam UMC, April 2024
Slide 4: Financial Performance
For personal use only Financial Performance
Slide 5: Financial Highlights
Financial Highlights • Net cash outflows from operating activities were US$4.7 million • The quarter included multiple non-recurring items For personal use only • Q2 operating costs expected to decrease below US$3.6 million • Net cash inflows from financing activities were US$5.1 million • After the
Slide 6: Key achievements in Q1 2024
For personal use only Key achievements in Q1 2024
Slide 7: Key Achievements: Reactivate European sites
Key Achievements Priority - Reactivate European sites For personal use only Hospital Dec 30th April 30th Comment Leipzig Heart Centre Active Active Only site active during Q1 Amsterdam UMC Pending Active Started cases in April Dubrava University Hospital Pending Active Catheters ordered, starting ca
Slide 8: Key Achievements: Gain FDA approval for Atrial Flutter
Key Achievements Priority – Gain FDA approval for Atrial Flutter - US launch in 2025 For personal use only • Reimbursement in US is about 4x higher than in Germany • US cardiac ablation market is approximately half of the global US$8 billion market Participating Hospital Johns Hopkins Cardiovascular
Slide 9: VISABL-AFL Trial – FDA Approval pathway
Key Achievements VISABL-AFL Trial – FDA Approval pathway For personal use only Trial details • Treatment of type 1 atrial flutter • Patients : 91 with possibility to end at 76 if primary endpoints are met (e.g. 80% acute success) • Participating hospitals : 4 • Expected completion : Q4 2024 • Expect
Slide 10: Priority – VISABL-VT Trial commencement
Key Achievements Priority – VISABL-VT Trial commencement • Doing an MRI guided left side of the heart ablation has been the primary goal of Imricor since inception For personal use only in 2006. A highly anticipated event for Imricor staff and the medical community at large. Requirement Status Hospi
Slide 11: Priority – Geographic Expansion
Key Achievements Priority – Geographic Expansion For personal use only Middle East entry • On track – 4 hospitals engaged across Saudi Arabia and Qatar. Capital sales and procedures expected early 2H 2024 Australia • TGA approval expected in current quarter Europe Approved for Sale • Continue expans
Slide 12: Operational Highlights
Operational Highlights • Site activation momentum under way For personal use only • April mtd consumable device revenue already more than Q1 • Amsterdam UMC, Dubrava, ICPS, CHUV. More sites in late stage • Middle East launch advancing – first sales expected during Q2 or early Q3. • Pipeline of new s
Slide 13: Contact Information
Contact Information For personal use only Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Investors: Steve Wedan Executive Chair, President & CEO steve.wedan@imricor.com Nick Corkill Vice President Corporate Strategy Nick.corkill@imricor.
Slide 14: Appendix
For personal use only Appendix FOLLOW US
Slide 15: Strong Engagement from Key Opinion Leaders
Strong Engagement from Key Opinion Leaders For personal use only “We are extremely excited to offer this to our patients and to lead the way forward with this new approach.” Professor Gerhard Hindricks MD PhD, Medical Director, Charité University Hospital “Today in our ablation we realized that we w
Slide 16: Strong Engagement from Key Opinion Leaders
Strong Engagement from Key Opinion Leaders For personal use only “With MRI-guided treatment of heart conditions, we are working towards fewer procedures per patient, fewer hospital admissions and less medication. Perhaps MRI- guided treatment of heart disease will then even become the norm and repla
Slide 17: NorthStar 3D Mapping System – The Central Hub of an iCMR Lab
NorthStar 3D Mapping System – The Central Hub of an iCMR Lab For personal use only NorthStar brings all iCMR technology together in one place • It controls the MRI • It receives MR images in real time • It displays everything in 3D • It tracks Imricor catheters • It facilitates electroanatomical map
Slide 18: A strong intellectual property portfolio
A strong intellectual property portfolio Imricor’s patents protect technology that For personal use only allows Imricor to manufacture medical devices that are uniquely MRI compatible. Imricor’s IP is relatively new, with the Company’s oldest issued patent expiring 19 issued U.S in 2030 Patents In a
Slide 19: Imricor Leadership
Imricor Leadership Management Board of Directors For personal use only Steve Wedan Jonathon Gut Gregg Stenzel Jennifer Weisz Nick Twohy Steve Wedan Mark Tibbles President and Chief Vice President of Chief Operating Vice President of Vice President of President and Chief Executive Deputy Chair and Le
Imricor Medical Systems — Q1 2024 Earnings Presentation on 6ix